Loading stock data…
Absci Corporation (ABSI)
$7.56-0.51 (-6.32%)
Market ClosedLast close Jul 24
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Absci Corporation in the Healthcare sector is trading at $7.56 with a market capitalization of $926M. Wall Street consensus targets $13.78 (9 analysts), implying a +82.2% move over the next 12 months. The stock is currently 37% below its 52-week high of $12.05, remaining 66.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 13 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +82.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 13) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $215,000↓ | $650,000↑ | $378,000↓ | $593,000↓ | $1.18M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$30.85M↑ | -$36.14M↓ | -$30.15M↑ | -$31.39M↓ | -$27.73M |
| Net Income | -$29.60M↓ | -$29.56M↓ | -$28.71M↑ | -$30.57M↓ | -$26.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bow...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$926.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-68.87%
Volume
Today's trading volume
2.52M
Recent News
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Absci Corporation stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, while also pricing a $100 million underwritten stock offering to support continued development of the program....
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
Amid the debut of positive Phase I data, the biotech will push its lead asset further down the clinical pipeline in endometriosis and pattern hair loss.